Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gsk Plc ADR
(NY:
GSK
)
43.74
-0.16 (-0.36%)
Official Closing Price
Updated: 6:30 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gsk Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
March 18, 2024
Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be revealed post book-building process by Haleon.
Via
Benzinga
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Via
InvestorPlace
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
March 11, 2024
Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success.
Via
InvestorPlace
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
March 11, 2024
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets.
Via
Benzinga
Looking Into GSK's Recent Short Interest
February 12, 2024
Via
Benzinga
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
March 07, 2024
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.
Via
InvestorPlace
GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study
March 07, 2024
GSK's DREAMM-8 trial reveals positive interim results for Blenrep combo in relapsed multiple myeloma. Improved progression-free survival and overall survival trend observed.
Via
Benzinga
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows
March 06, 2024
Findings from ViiV Healthcare's LATITUDE trial on long-acting HIV treatment. Cabenuva demonstrates superior efficacy in viral load suppression compared to daily oral therapy. Key secondary endpoints...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 06, 2024
Via
Benzinga
Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance, WHO Report Says
March 05, 2024
WHO's latest HIV Drug Resistance Report reveals trends in drug resistance. Discover insights on dolutegravir's impact, challenges in HIVDR monitoring, and recommendations for standardized...
Via
Benzinga
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges
March 04, 2024
The Biden administration wants insurers to cover preventive care, facing opposition from businesses led by Braidwood Management.
Via
Benzinga
Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars
February 29, 2024
Haleon reports FY 2023 revenue growth of 4.1% to £11.3 billion ($14.03 billion), missing consensus. Adjusted operating profit rises 10.4% to £2.55 billion. CEO Brian McNamara outlines solid financial...
Via
Benzinga
GSK Settles Another California Lawsuit On Heartburn Drug Zantac Causing Cancer, Second Within A Month
February 29, 2024
GSK settles California lawsuits over Zantac cancer allegations. Confidential agreements reached, cases dismissed.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
February 28, 2024
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.
Via
Benzinga
GSK's Gepotidacin Oral Antibiotic Non-Inferior To Commonly Used Muscle-Injected Antibiotic Combo For Sexually Transmitted Infection
February 26, 2024
Results from GSK's EAGLE-1 phase 3 trial on gepotidacin, an oral antibiotic for uncomplicated urogenital gonorrhea. Non-inferior to leading treatment, it offers a potential solution amid rising...
Via
Benzinga
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List
February 22, 2024
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price.
Via
InvestorPlace
Why Range-Bound Moderna Could Get A Boost On Its Fourth-Quarter Report
February 22, 2024
The company unexpectedly came in with fourth-quarter earnings that beat projections.
Via
Investor's Business Daily
Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus
February 21, 2024
Moderna reports Q4 earnings on Feb. 22. Analysts expect $2.53B in revenue. Stock has faced challenges but potential for recovery with COVID-19 vaccine and FDA approval in 2024.
Via
Benzinga
Exposures
COVID-19
Product Safety
3 Low-Priced Dividend Stocks With Solid Fundamentals & Growth
February 21, 2024
Solid dividend stocks with good growth outlooks can deliver high profits for investors and should become more popular as interest rates drop.
Via
InvestorPlace
Dividend Income Update January 2024
February 15, 2024
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio
Via
Talk Markets
Why Is Moderna Stock Trading Lower Today?
February 09, 2024
Moderna long term data indicates a faster decline in efficacy for its RSV vaccine than the RSV vaccines from GSK and Pfizer.
Via
Benzinga
Jim Cramer Expects Drugmaker Stock To Go 'Even Higher,' As For Kroger: 'What The Heck Is Going On?'
February 06, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer believes in GSK plc (NYSE: GSK).
Via
Benzinga
The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024
February 06, 2024
Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements.
Via
InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Novavax's Malaria Vaccine Gets WHO Prequalification, Has Potential Of Being An Affordable Option
February 02, 2024
Novavax's R21/Matrix-M malaria vaccine, with 75% efficacy in seasonal areas. Affordable at $3 per dose, it outshines GSK's vaccine. Global rollout expected mid-2024.
Via
Benzinga
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
What's Going On With GSK Stock Today?
February 01, 2024
GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections
January 31, 2024
Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired.
Via
Investor's Business Daily
GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine
January 31, 2024
GSK's robust Q4 performance with a 21% YoY increase in adjusted operating profit. Arexvy vaccine sales hit £1.2B in 2023. Outlook for 2024, with 5%-7% sales growth and upgraded long-term projections.
Via
Benzinga
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
January 31, 2024
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.